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Abstract
Background: Pneumococcal meningitis (PM) remains a global public health concern and affects all age groups. If
acquired during infancy or childhood, permanent neurofunctional deficits including cognitive impairment, cerebral
palsy, and secondary epilepsy are typical sequelae of neuronal injury. Determination of patients at risk for the
development of brain injury and subsequent neurofunctional sequelae could help to identify patients for focused
management. Neurofilament light chain (NfL) is an axonal cytoskeletal protein released upon neuronal injury into
the cerebrospinal fluid (CSF) and blood. As little is known about the course of neurofilament release in the course
of PM, we measured CSF and serum NfL levels longitudinally in experimental PM (ePM).
Methods: Eleven-day-old infant Wistar rats were infected intracisternally with Streptococcus pneumoniae and treated
with ceftriaxone. At 18 and 42 h post-infection (hpi), the blood and CSF were sampled for NfL measurements by a
single molecule array technology. Inflammatory cytokines and MMP-9 in CSF were quantified by magnetic bead
multiplex assay (Luminex®) and by gel zymography, respectively.
Results: In ePM, CSF and serum NfL levels started to increase at 18 hpi and were 26- and 3.5-fold increased,
respectively, compared to mock-infected animals at 42 hpi (p < 0.0001). CSF and serum NfL correlated at 18 hpi (p
< 0.05, r = 0.4716) and 42 hpi (p < 0.0001, r = 0.8179). Both CSF and serum NfL at 42 hpi strongly correlated with
CSF levels of IL-1β, TNF-α, and IL-6 and of MMP-9 depending on their individual kinetics.
Conclusion: Current results demonstrate that during the peak inflammatory phase of ePM, NfL levels in CSF and
serum are the highest among CNS disease models studied so far. Given the strong correlation of CSF versus serum
NfL, and its CNS-specific signal character, longitudinal measurements to monitor the course of PM could be
performed based on blood sample tests, i.e., without the need of repetitive spinal taps. We conclude that NfL in the
serum should be evaluated as a biomarker in PM.
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Background
Streptococcus pneumoniae and Neisseria meningitidis are
the most prevalent causative pathogens for childhood
bacterial meningitis (BM) [1] with fatality rates up to
50% in resource-poor settings [2]. Pneumococcal menin-
gitis (PM) acquired during infancy or childhood is asso-
ciated with a high risk for neurofunctional deficits which
profoundly affect the quality of life. One-third of PM
survivors display long-lasting neurological sequelae in-
cluding hearing loss, cerebral palsy, secondary epilepsy,
and cognitive impairment [3, 4].
In reaction to the bacterial infection, the host’s immune
response causes an excessive inflammation that leads to
injury to the central nervous system (CNS) [4, 5]. The
brain structural damage induced in the course of PM re-
sults also from vasospasms and reduced blood flow that
eventually cause cortical necrosis [6] and apoptotic cell
death in the hippocampal subgranular zone of the dentate
gyrus [7–9]. Additionally, brain-diffuse ischemic axonal
injury and Wallerian degeneration have been demon-
strated in brain autopsy of human BM and in experimen-
tal PM (ePM) [10]. Along with inflammatory signaling
molecules like IL-1β, TNF-α, and IL-6, effector molecules
such as matrix metalloproteinases (MMPs) are released in
high amounts into the cerebrospinal fluid (CSF) [11], pro-
moting blood-brain barrier (BBB) opening and neutrophil
recruitment [12, 13] and may exert as well direct toxicity
on neurons [14, 15]. While their levels are linked to the
likelihood for long-term sequelae [11, 14], their relevance
as biomarkers in clinical practice is limited, as they reflect
disease activity only in CSF, but not in the serum. Hence,
longitudinal spinal taps would be required to use them for
disease monitoring. Functionally, they relate to neuronal
damage only indirectly and no biofluid marker has been
established in BM that measures neuronal damage itself.
Neurofilaments (NFs) are a major component of the
axonal cytoskeleton and consist of three subunits: NF light
chain (NfL), medium chain, and heavy chain. Upon axonal
damage, NFs are released into the extracellular space and
eventually into the CSF and blood. Their increased levels
can be used as a biomarker of neuronal damage [16], indi-
cative of actual disease activity and predicting later disease
course in neurodegenerative diseases (multiple sclerosis
[17], Alzheimer’s and Parkinson’s disease [18], Huntington
disease [19], and amyotrophic lateral sclerosis (ALS) [20]),
traumatic brain injury [21], and viral and autoimmune
encephalitis [22].
With the advent of the single-molecule array (Simoa)
technology, the sensitivity for quantitation of NfL has been
increased to a degree that levels in serum or plasma can
be accurately quantified [23]. This technical progress, the
specificity of the signal as of exclusive neuronal origin and
the strong correlation between CSF and serum NfL dem-
onstrated in numerous studies, made it possible to use a
serum instead of CSF-based analysis. Thus, longitudinal
assessment as an inherent prerequisite to specifically
monitor CNS disease activity and drug response can be
implemented based on blood tests whose acquisition is far
less invasive than repetitive lumbar puncture [24].
Only one study has evaluated NFs as a biomarker for
neuronal injury in BM across an array of infectious
agents. CSF concentrations of NF heavy chain were in-
creased by 85% (22/26) children with BM; peak levels in
patients with neurological sequelae were significantly
higher than in those without [25].
Present results are the first to investigate the course of
NfL in ePM. We hypothesized that serum NfL is a useful
biomarker to monitor disease activity in BM, as its kinetics
accurately correlated with those in CSF, as well as with
typical inflammatory mediators upregulated in ePM.
Methods
Infecting organism
A clinical isolate of Streptococcus pneumoniae (serotype 3)
was cultured overnight in brain heart infusion (BHI)
medium, diluted tenfold in fresh, prewarmed BHI
medium, and grown for 5 h to reach the logarithmic
phase. The bacteria were centrifuged for 10min at 3100 ×
g at 4 °C, washed twice, and resuspended in saline (NaCl
0.85%). The resuspended bacterial solution was then
further diluted in saline to the desired optical density
(OD570nm). The inoculum concentration was determined
by serial dilution and culturing on Columbia sheep blood
agar (CSBA) plates.
Infant rat model of ePM
All animal studies were approved by the Animal Care and
Experimentation Committee of the Canton of Bern,
Switzerland (license no. BE 01/18). A well-established in-
fant rat model of PM was used [26, 27]. Eleven-day-old
male and female Wistar rat pups together with their dams
were purchased from Charles Rivers (Sulzfeld, Germany).
The dams were provided with tap water and pellet diet ad
libitum. Animals were kept in a room at controlled
temperature (22 ± 2 °C) and natural light. Intracisternal
injections were performed on pups by injection of 10 μl of
the inoculum containing 5.25 ± 3.4 × 105 CFU/ml of living
S. pneumoniae serotype 3. Control animals received an
equivalent volume of saline. PM was confirmed by the
quantitative analysis of bacterial titers in the cerebrospinal
fluid (CSF) at 18 hpi. Five microliters of CSF was gained
by puncture of the cisterna magna, followed by serial dilu-
tion and cultivation on CSBA plates. To confirm PM in
animals which were not punctured at 18 hpi, the blood
was cultivated on CSBA plates. The numbers of animals
per independent experiments was determined by a max-
imum litter size of 14 pups. Given the probability of pre-
mature abortion of experiments due to reaching humane
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endpoints or spontaneous death in infected animals, or
unsuccessful infection, experiments were designed with 4
mock-infected and 10 infected animals per experiment.
Four independent experiments were performed, for a total
of 56 animals. Animals without confirmed PM were
excluded (n = 9). All animals received ceftriaxone (100
mg/kg, i.p., twice daily [b.i.d.]) at 18 and 24 hpi. With the
dosing regimen applied in the present study, therapeutic
concentrations are maintained until the end of the experi-
ment, so there is no resurgence of bacterial infection at
later time points. Animals were weighed and clinically
scored according to the following scoring scheme (1 =
coma, 2 = does not turn upright, 3 = turns upright in >5 s,
4 = turns upright in <5 s, 5 = normal) at 0, 18, 24, and be-
fore sacrificing at 42 hpi. Spontaneous mortality was doc-
umented. Blood sampling in all animals was performed at
18 hpi by puncturing the facial vein using a 20-gauge nee-
dle. Blood (< 10% of total blood volume) was collected in
Microvette® 200 Z (clotting activator/serum) (Sarstedt),
kept at room temperature for at least 30min, and then
centrifuged for 10min at 13,000 × g at 4 °C. The super-
natant (serum) was collected and kept at − 80 °C for later
analysis. Following blood sampling, CSF samples of half of
the animals (n = 28) were obtained by puncture of the
cisterna magna using a 30-gauge needle. CSF samples
were only collected from half of the animals to assess if
this additional puncture causes an artefactual increase in
NfL level. CSF samples were then centrifuged for 10min
at 13,000 × g at 4 °C, and supernatants were stored at −
80 °C for later use. Animals were treated with ceftriaxone
after the collection of specimens. At 42 hpi, the blood and
then CSF were sampled again from all animals, followed
by sacrificing with pentobarbital (Esconarkon®, 150mg/kg,
i.p., Streuli Pharma AG, Switzerland). Of note, throughout
the experiment, each animal was only punctured once to
avoid a possible artificial increase of NfL in CSF and
serum by multiple puncturing. Accordingly, if an animal
was not punctured successfully or died spontaneously, no
CSF could be collected which then resulted in lower
datapoints.
Analysis of cytokine levels in CSF
Cytokines known to be upregulated in PM (IL-1β, TNF-
α, IL-6) were assessed using a magnetic multiplex assay
(Rat Magnetic Luminex® Assay, Rat Premixed Multi-
Analyte Kit, R&D Systems, Bio-Techne) on a Bio-Plex
200 station (Bio-Rad Laboratories) as earlier reported
[27]. Five microliters of CSF collected at 18 and 42 hpi
were diluted to a final volume of 50 μl. For each sample,
a minimum of 50 beads was measured. For samples
below the detection limit, a value corresponding to the
detection limit provided by the manufacturer was used
and multiplied by the dilution factor (IL-1β 2.93 pg/ml;
TNF-α 11.5 pg/ml; IL-6 23.2 pg/ml).
Analysis of NfL levels in CSF and serum
NfL in CSF and serum were analyzed using a SIMOA®
immunoassay (Quanterix Corporation, Billerica, MA,
USA) as previously described [17]; the antibody pair of
this assay is full cross-reactive with murine NfL.
Analysis of MMP-9 levels in CSF
The amount of MMP-9 in CSF was assessed by gel zymo-
graphy as reported earlier [11]. Briefly, CSF samples (2 μl)
were diluted with 5 μl of 4× sample buffer (0.5M Tris-
HCl pH 6.8, 10% sodium dodecyl sulfate (SDS) 20%, 42.5%
glycerol, 0.5% bromophenol blue) and 13 μl of distilled
water (dH2O) to a loading volume of 20 μl and electro-
phoresed under non-reducing conditions in 10% SDS-
polyacrylamide gels containing type A gelatin from por-
cine skin (1%; Sigma, Buchs, Switzerland) as proteinase
substrate. After electrophoresis for 2 h at 100 V, gels were
incubated for 2 × 30min in SDS-removing buffer (1% Tri-
ton X-100), washed 5× with dH2O, followed by incubating
in incubation buffer (1.5M NaCl, 0.5M Tris-HCl pH 7.6,
4% NaN3, 10mM CaCl2) for 18 h at 37 °C on a shaker.
Gels were then stained with Coomassie blue (0.05% Coo-
massie blue in 40% methanol, 10% glacial acid, 50%
dH2O) to visualize the substrate lysis zones of MMP-9
(92 kDa) and MMP-2 (72 kDa). The gelatinolytic activities
of MMP-9 and MMP-2 were analyzed using ImageJ soft-
ware. The amount of expressed MMP-9 was determined
as a percentage of that of the constitutively expressed
MMP-2 for each sample [26].
Statistical analysis
Statistical analyses were performed with GraphPad Prism
(Prism 7; GraphPad Software Inc., San Diego, USA). Data
were first tested for normal distribution with the
Kolmogorov-Smirnov test.
To compare the differences between the non-normally
distributed data, a non-parametric Mann-Whitney test
was used. Correlations were assessed by using the Spear-
man correlation coefficient. The results are presented as
median with interquartile range. A p value of 0.05 was
considered as statistically significant, with *p < 0.05, **p
< 0.01, ***p < 0.001, and ****p < 0.0001.
Results
Intracisternal puncture causes a minor increase in CSF NfL
levels
In the present ePM model, intracisternal punctures are
performed to inoculate S. pneumoniae or saline in a first
step and to collect CSF samples later. To determine
whether this mechanical trauma leads to an artifactual
neuronal damage, we measured serum NfL levels of ani-
mals before any intervention and compared them with
animals at 18 hpi which have been inoculated with saline
at baseline.
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Baseline levels of serum NfL of animals before any inter-
vention (mean ± SD; 299.1 ± 26.4 pg/ml) were not differ-
ent from those of mock-infected animals at 18 hpi (293.7
± 168.3 pg/ml) (p = 0.18) (Fig. 1a), indicating that the first
intracisternal puncture for the inoculation of S. pneumo-
niae or saline had no impact on serum levels. In mock-
infected animals undergoing a second intracisternal punc-
ture at 18 hpi for CSF collection, serum levels (471.4 ±
318.6 pg/ml) at 42 hpi increased 1.6-fold compared to
those having been punctured only at baseline (299.3 ±
137.2 pg/ml) (p = 0.33). Accordingly, CSF levels of NfL
showed a 1.8-fold increase in animals having had a second
intracisternal puncture (789 ± 303.9 pg/ml) compared to
those without (436.7 ± 163.2 pg/ml) (p = 0.01) (Fig. 1b). In
contrast, at 42 hpi CSF and serum NfL levels in infected
animals were more than 2000% (15,319.6 ± 36,745.4 pg/
ml) and 300% (1307.5 ± 1062.6 pg/ml) increased, respect-
ively (pooled analysis of 18 hpi punctured and non-
punctured) (Fig. 1c), compared to levels in mock-infected
animals (Fig. 1b). We conclude that the second intracister-
nal puncture at 18 hpi did cause a microtrauma, possibly
contributing to a < 2% increase of NfL levels in CSF of the
total amount observed in the course of ePM, while serum
levels in infected animals were not impacted by a second
intracisternal puncture. We therefore have pooled the two
groups (with and without second intracisternal puncture)
for further analyses.
Animals with ePM have increased CSF and serum NfL
concentrations
In the next experiment, we evaluated the time course of
NfL increase in infected animals. At 18 hpi, CSF NfL con-
centrations (2517.1 ± 3336.3 pg/ml) trended to be higher
compared to mock-infected animals (590.1 ± 186.9 pg/ml)
(p = 0.06) and at 42 hpi, they showed a 26-fold higher level
(15,319.6 ± 36,745.4 pg/ml) compared to mock-infected
controls (590.1 ± 296.4 pg/ml) (p < 0.0001) (Fig. 2a). At
the same time point, serum NfL levels of infected animals
(1362.8 ± 1136 pg/ml) were 3.5-fold higher than mock-
infected animals (385.4 ± 253.1 pg/ml) (p < 0.0001), while
at 18 hpi the levels between the two groups were similar
(Fig. 2b). The relative increase of NfL levels over time in
infected animals was highly significant in both CSF (p <
0.01) and in serum (p < 0.0001), whereas those of mock-
infected animals remained stable in both fluid compart-
ments (Fig. 2a, b).
At 18 hpi NfL levels in CSF and serum were correlated
(p < 0.05, r = 0.4716) with an average CSF concentration
(1908.6 ± 2877 pg/ml) being 6.9-fold higher than that in
serum (276.9 ± 144.8 pg/ml) (Fig. 2c). A stronger correl-
ation was also observed at 42 hpi (p < 0.0001, r = 0.8179)
with average CSF levels (9848.6 ± 29768 pg/ml) being 9.8-
fold higher than in serum (1007.3 ± 1029 pg/ml) (Fig. 2d).
Kinetics of cytokines and MMP-9 upregulation in the
course of ePM
We measured the dynamic change of inflammatory cyto-
kines TNF-α, IL-6, and IL-1β and of MMP-9 during the
acute phase of ePM and correlated values with those of
NfL. The concentrations of all cytokines were upregulated
in infected animals at 18 hpi compared to mock-infected
animals (Fig. 3a–c) but decreased at 42 hpi to similar
levels as in mock-infected ones for TNF-α and IL-6; only
IL-1β remained higher in infected versus mock-infected
animals (p = 0.02) (Fig. 3c). The relative amount of MMP-
9 (MMP-9/MMP-2 index) followed a similar kinetic with
increased levels in infected compared to mock-infected
Fig. 1 Effect of intracisternal puncture on NfL level. a Serum NfL levels of animals (n = 3) before any intervention and mock-infected animals at
18 hpi (n = 16) were similar. b At 42 hpi, mock-infected animals punctured a second time at 18 hpi (n = 7) demonstrated higher CSF NfL levels
(p = 0.01), while there was only a trend for higher serum NfL levels (n = 8) compared to non-punctured animals at 18 hpi (CSF n = 7; serum n =
8). c In infected animals, second time punctured (CSF n = 6; serum n = 10) and not punctured animals (CSF n = 16; serum n = 17) displayed
similar NfL levels both in CSF and serum at 42 hpi
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animals at 18 hpi (p < 0.001) and 42 hpi (p < 0.0001)
(Fig. 3d).
Cytokine levels correlated among each other at 18 hpi
(all p < 0.0001; Suppl. Fig. 1). This was not the case for
the correlation of cytokine levels with MMP-9, except
for IL-1β at 18 hpi (p = 0.04, r = 0.5126) and a trend at
42 hpi (p = 0.07, r = 0.3940) (Suppl. Fig. 2).
Table 1 shows the correlation of CSF cytokine and
MMP-9 levels with NfL at different time points and for
both fluid compartments. At 18 hpi, TNF-α, IL-6, and
IL-1β correlated with CSF NfL but not with serum NfL.
In addition, cytokine levels at 18 hpi correlated with
both CSF and serum NfL at 42 hpi, with the exception
of TNF-α that the set significance level for CSF NfL was
missed by a margin. At 42 hpi, levels of IL-1β correlated
with NfL in both fluid compartments. Moreover, MMP-
9 levels at 18 and 42 hpi were correlated with serum
NfL at 42 hpi, while for CSF NfL this correlation became
significant only at 42 hpi.
Discussion
Neurofilament light chain has been established in recent
years as a neuron-specific marker of damage within the
CNS, reflecting disease activity and therapy response in
many neurological diseases [23, 28] and is now at the
doorstep of clinical application [24]. However, little is
known about whether NfL could be clinically useful in
the same capacity in BM.
In the present study, we investigated the course of NfL re-
lease in ePM, a well-characterized model closely replicating
the pathology of human PM. Here, neuronal damage is usu-
ally more severe and acute than in most other neurological
diseases, but there is currently no biomarker established to
specifically measure this injury directly. Increased concen-
trations of neuron-specific enolase (NSE) have been found
in patients [29] and in animal models [30], but this marker
is not specific for neuronal damage in CSF, as neuroendo-
crine tissues outside the CNS, most prominently in the lung,
are important cellular sources. S100B is an astrocyte-
Fig. 2 The course of NfL in experimental PM. a, b At 18 hpi, infected animals displayed non-significantly increased CSF NfL levels (n = 13)
compared to mock-infected animals (n = 6), whereas both displayed similar levels in serum NfL (mock-infected n = 16; infected n = 30). At 42
hpi, infected animals showed a significant increase of NfL levels in CSF (n = 22) and serum (n = 28) compared to mock-infected ones (p < 0.0001)
(CSF n = 13; serum n = 16). In mock-infected animals, both CSF and serum NfL levels remained stable between 18 and 42 hpi. NfL levels in CSF
and serum showed a correlation at 18 hpi (p < 0.05, r = 0.4716; n = 18) (c) and at 42 hpi (p < 0.0001, r = 0.8179; n = 35) (d)
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derived marker of brain damage [31]. Several studies have
reported an increase of S100B in CSF of human BM [32,
33] and in a rabbit model of PM [31]. However, S100B con-
centrations already peaked at 20 h after experimental infec-
tion and have a short serum half-life which may explain a
high percentage of negative scores [34]. These factors may
elucidate why both markers have not become standard tests
in clinical settings, together with the fact that repetitive lum-
bar puncture to rely on CSF measurements is impracticable.
In contrast, the strong correlation of serum and CSF
measures of NfL makes it an ideal marker to monitor
CNS-based pathology. Present results demonstrate that
NfL is upregulated in CSF and serum during ePM and
confirm the close relationship between the two fluid com-
partments. Further, we showed that the increase of pro-
inflammatory cytokines TNF-α, IL-6, and IL-1β in CSF
during an early stage of the disease correlated with the
later degree of NfL release. Accordingly, CSF levels of
MMP-9, an effector molecule of tissue damage that is re-
leased in the function of cytokine expression [35, 36], were
also quantitatively linked to the amount of NfL release.
The correlation of CSF cytokines and CSF cell counts has
been described elsewhere [37, 38] while no correlation has
been demonstrated between CSF cell counts and CSF NF
in patients with BM [25].
Because our kinetic CSF study required cisterna magna
punctures at two different time points in the same animal,
we had to evaluate whether this procedure does lead to
artifactual neuronal damage interfering with disease-
related levels of NfL. The baseline intracisternal puncture
with saline did not cause an increase in serum NfL concen-
tration as compared to animals without any intervention.
As our primary interest is to demonstrate the value of NfL
as a serum-based marker for ePM and to limit the use of
animals, we therefore refrained from performing referring
CSF measurements.
At 42 hpi, mock-infected animals punctured for a second
time at 18 hpi for CSF collection showed a small increase
of CSF NfL concentrations compared to animals punc-
tured only at baseline, while serum levels were unaffected.
Fig. 3 Inflammatory CSF cytokines and MMP-9/MMP-2 levels during ePM. At 18 hpi before treatment with ceftriaxone, infected animals displayed
significant higher TNF-α (p = 0.01) (n = 11) (a), IL-6 (p < 0.001) (n = 12) (b), IL-1β (p < 0.001) (n = 12) (c), and MMP-9/MMP-2 (p < 0.001) (n = 12)
(d) levels compared to mock-infected animals (n = 5 for all cytokines and MMP9-/MMP-2). At 42 hpi, concentrations of TNF-α (a) and IL-6 (b)
were similar in mock-infected (n = 8; n = 11) and infected animals (n = 6; n = 18) whereas IL-1β (p = 0.02) (n = 17) (c) and MMP-9/MMP-2 (p <
0.0001) (n = 17) (d) were still higher in infected compared to mock-infected ones (n = 12; n = 7)
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We conclude that this intervention, likely in combination
with a local inflammation due to the first puncture, caused
a minor neuronal damage. Because the amount of artifac-
tually induced NfL release was less than 2% of that found
in ePM at 42 hpi, we conclude that the NfL levels mea-
sured are almost exclusively reflective of the infection-
related pathology.
NfL can reach the systemic circulation by the bulk flow
through the ventricular system and then exiting into the
subarachnoid space where it is then reabsorbed into the
blood stream [39]. In addition to this, current results sug-
gest that in the initial phase of the disease, the BBB and
blood-CSF barrier (BCSFB) are mainly intact, and only
small amounts of NfL can reach the circulation. As a con-
sequence of the BBB opening in the course of disease, the
correlation of NfL in CSF and serum becomes stronger
over time, and the correlation of serum levels with those
of CSF cytokines seems to reflect the degree of neuroin-
flammation in blood circulation.
In ePM, TNF-α, IL-6, and IL-1β appear early, prior to
neutrophil recruitment, indicating that they are released
by brain-resident cells [40, 41]. TNF-α was shown to ap-
pear already 4 h after infection, reaching the peak at 12 h
and persisting until 20 h after infection [26]. While the
surge of cytokines released at this stage seems to directly
lead to later neuronal damage, the induction of MMP-9
by these stimuli may be a further enhancing factor.
MMP-9 induces degradation of the BBB and therefore
facilitates leukocyte extravasation [12, 40]. Additionally,
MMP-9 activates and regulates cytokine signaling in a
positive feedback loop, enhancing the excessive inflam-
mation [42, 43] and is suggested to play a role in glial
and neuronal cell death [44] and development of neuro-
logical sequelae after PM [14].
During BM, microglia are activated by several stimuli in-
cluding pathogen-associated and damage-associated mo-
lecular patterns (PAMPs & DAMPs) and pro-inflammatory
mediators, leading to the production of cytokines and che-
mokines. Nevertheless, excessive microglial activation can
result in neuronal damage [45]. In the present study, we did
not analyze the microglial status between 18 and 42 hpi.
Previously, the microglia status was investigated at the mor-
phological levels at 24 and 42 hpi, showing a transform-
ation of thick ramified to amoeboid, phagocytic phenotype
[46]. Since inflammation in the CSF is also resulting from
the leucocytic infiltration, it is difficult to determine the
Table 1 Correlation of inflammatory cytokines, MMP-9, and NfL in CSF and serum. Green = p < 0.05, yellow = a trend towards p <
0.05, red = non-significant
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specific involvement of microglia. At the transcriptomic
level in the cortical tissue, a decrease of the component of
the Toll-like receptor pathways between 24 and 72 hpi was
observed while there was an increase of the expression of
genes guided by the clearance of tissue damage and regen-
eration [46].
This study has several limitations. We used an experi-
mental model where bacteria are directly injected into the
CSF which therefore does not reflect the natural course of
the disease. Nonetheless, this method showed a higher
success rate compared to methods of hematogenous infec-
tion, where successful meningitis is only developed in
around 50% [47, 48]. In addition, it is a useful model for
studying the interaction between the host and the patho-
gen as well as the complications resulting from the dis-
ease. Next, we only focused on the disease phase of PM
up to 42 hpi, with inflammatory cytokine concentrations
showing their peak between 18 and 24 hpi in infected ani-
mals and a resolution to almost background levels at 42
hpi [27, 49]. The kinetic of NfL after 42 hpi and during
the recovery processes has not been determined yet. Fur-
ther longitudinal investigations with later time points will
be needed to assess the kinetic of NfL release and its cor-
relation with chronic clinical sequelae of PM.
In the present study, the degree of cortical damage
was limited and gross cortical necrosis was not observed
(data not shown) and NfL release resulted mainly from
brain-diffuse damage. The correlation of NfL release
with defined morphological features of a neuronal dam-
age is the next step underway in our laboratory.
Nevertheless, this study indicates that NfL is a very sensitive
marker able to quantitate neuronal damage before it mani-
fests with the most severe stage of typical PM pathology.
Conclusion
During the acute phase of BM, the upregulation of inflam-
matory mediators causes neuronal damage. Although in-
flammatory mediators could be used as predictors, they are
not a direct indicator of neuronal injury. Furthermore, a
clinically useful biomarker for BM needs to be blood-based
to avoid the invasive procedure of lumbar puncture. Serum
NfL is a sensitive biomarker which reflects neuronal
damage with high specificity. Given the strong correlation
between CSF and serum, current results provide the con-
ceptual evidence for the use of NfL as a promising bio-
marker for the evaluation of neuroprotective agents in BM.
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